Cidara Therapeutics Inc.

Cidara Therapeutics Inc functions in the healthcare sector based in the United States. Its business involves the development of novel anti-infectives for the treatment of serious infections, especially caused due to fungus. The company’s main drug constitutes echinocandins antifungals in the form of CD101IV and CD101 topical. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis. In addition, Cidara has developed a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious diseases.